The role of PI3K isoforms in regulating bone marrow microenvironment signaling focusing on acute myeloid leukemia and multiple myeloma
RE Piddock, KM Bowles, SA Rushworth - Cancers, 2017 - mdpi.com
Despite the development of novel treatments in the past 15 years, many blood cancers still
remain ultimately fatal and difficult to treat, particularly acute myeloid leukaemia (AML) and …
remain ultimately fatal and difficult to treat, particularly acute myeloid leukaemia (AML) and …
Molecular targets for the treatment of multiple myeloma
Multiple myeloma (MM) represents a suitable disease to be treated with Molecularly targeted
drugs (MTDs). MM clone aberrations affect signal transduction pathways controlling both …
drugs (MTDs). MM clone aberrations affect signal transduction pathways controlling both …
LncRNA HCP5 promotes cell proliferation and inhibits apoptosis via miR-27a-3p/IGF-1 axis in human granulosa-like tumor cell line KGN
Y Chen, X Zhang, Y An, B Liu, M Lu - Molecular and cellular endocrinology, 2020 - Elsevier
This study aimed to reveal the potential roles of long non-coding RNA HCP5 (lncRNA
HCP5) and its potential molecular mechanism in polycystic ovarian syndrome (PCOS). The …
HCP5) and its potential molecular mechanism in polycystic ovarian syndrome (PCOS). The …
MUC1-C drives MYC in multiple myeloma
A Tagde, H Rajabi, A Bouillez, M Alam… - Blood, The Journal …, 2016 - ashpublications.org
Multiple myeloma (MM) cell lines and primary tumor cells are addicted to the MYC
oncoprotein for survival. Little is known, however, about how MYC expression is upregulated …
oncoprotein for survival. Little is known, however, about how MYC expression is upregulated …
APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status
J Quinn, J Glassford, L Percy, P Munson… - Blood, The Journal …, 2011 - ashpublications.org
A proliferation-inducing ligand (APRIL) promotes survival and drug resistance in multiple
myeloma (MM) cell lines. We studied the effect of APRIL on cell-cycle behavior in primary …
myeloma (MM) cell lines. We studied the effect of APRIL on cell-cycle behavior in primary …
Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma
S Yokokura, S Yurimoto, A Matsuoka, O Imataki… - BMC cancer, 2014 - Springer
Background Human multiple myeloma (MM) is an incurable hematological malignancy for
which novel therapeutic agents are needed. Calmodulin (CaM) antagonists have been …
which novel therapeutic agents are needed. Calmodulin (CaM) antagonists have been …
RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma
Y Shimura, J Kuroda, M Ri, H Nagoshi… - Molecular cancer …, 2012 - AACR
Multiple myeloma is an entity of cytogenetically and genetically heterogenous plasma cell
neoplasms. Despite recent improvement in the treatment outcome of multiple myeloma by …
neoplasms. Despite recent improvement in the treatment outcome of multiple myeloma by …
[HTML][HTML] CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model
N Imayoshi, M Yoshioka, J Chauhan, S Nakata… - Biochemical and …, 2017 - Elsevier
Multiple myeloma (MM) is characterized by the clonal proliferation of neoplastic plasma
cells. Despite a stream of new molecular targets based on better understanding of the …
cells. Despite a stream of new molecular targets based on better understanding of the …
Biphasic ER-α36-mediated estrogen signaling regulates growth of gastric cancer cells
X Wang, X Huang, Z Fu, F Zou… - … journal of oncology, 2014 - spandidos-publications.com
To examine the expression patterns of ER-α36 and Cyclin D1 in human gastric cancer
tissues and to investigate the effects of ER-α36-mediated estrogen signaling on the growth …
tissues and to investigate the effects of ER-α36-mediated estrogen signaling on the growth …
Cyclin D type does not influence cell cycle response to DNA damage caused by ionizing radiation in multiple myeloma tumours
Multiple myeloma (MM) is characterized by over‐expression of cyclin D1 (CCND 1) or D2
(CCND 2), which control G1 phase cell‐cycle progression. Proteolytic degradation of CCND …
(CCND 2), which control G1 phase cell‐cycle progression. Proteolytic degradation of CCND …